Influence of brain injury on early posttraumatic bone metabolism

Critical Care Medicine

Volumn 33, Issue 2, 2005, Pages 399-406

  Trentz, Omana A ^a   Handschin, Alexander E ^a   Bestmann, Lukas ^a   Hoerstrup, Simon P ^a   Trentz, Otmar L ^a   Platz, Andreas ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Bone markers; Heterotopic ossification; Osteocalcin; Traumatic brain injury

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CALCITONIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 1 PYRIDINOLINE CROSS LINKED TELOPEPTIDE DOMAIN; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE DEVELOPMENT; BONE METABOLISM; BONE REMODELING; BRAIN FUNCTION; BRAIN INJURY; CALCIUM BLOOD LEVEL; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FRACTURE; FRACTURE HEALING; HETEROTOPIC OSSIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC BALANCE; OSSIFICATION; OSTEOLYSIS; PARAMETER; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ADULT; ALKALINE PHOSPHATASE; BONE AND BONES; BONE REMODELING; BRAIN INJURIES; CALCITONIN; CALCIUM; COLLAGEN; COLLAGEN TYPE I; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSSIFICATION, HETEROTOPIC; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHORUS; PROCOLLAGEN;

EID: 13444283300     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000152221.87477.21     Document Type: Article

References (44)

1. Calvo MS, Eyre DR, Gundberg CM: Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 1996; 17:333-368
2. Christenson RH: Biochemical markers of bone metabolism: An overview. Clin Biochem 1997; 30:573-593
3. Bidner S, Rubins J, Desjardins J, et al: Evidence for a humoral mechanism for enhanced osteogenesis after head injury. J Bone Joint Surg Am 1990; 72:1144-1149
4. Keret D, Harcke HT, Mendez AA, et al: Heterotopic ossification in central nervous system-injured patients following closed nailing of femoral fractures. Clin Orthop 1990; 25:254-259
5. Banovac K, Gonzalez F: Evaluation and management of heterotopic ossification in patients with spinal cord injury. Spinal Cord 1997; 35:158-162
6. Garland DL, Blum CE, Waters RL: Periarticular heterotopic ossification in head-injured adults. J Bone Joint Surg 1980; 62:1143-1146
7. Jensen LL, Halar E, Little JW, et al: Special review. Neurogenic heterotopic ossification. Am J Phys Med 1988; 66:351-363
8. Goodman TA, Merkel PA, Perlmutter G, et al: Heterotopic ossification in the setting of neuromuscular blockade. Arthritis Rheum 1997; 40:1619-1627
9. Konttinen YT, Imai S, Suda A: Neuropeptides and the puzzle of bone remodelling. Acta Orthop Scand 1999; 67:632-639
10. Trentz OA, Uhlschmid GK, Bösch C: Involvement of calcitonin gene-related peptide (CGRP) and its receptor (CGRP-R) in posttraumatic bone growth and remodelling. Eur J Trauma 2001; 2:34-41
11. Chenu S, Serre CM, Raynal C, et al: Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone 1998; 22:295-299
12. Merle B, Itzstein C, Delmas PD, et al: AMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. J Cell Biochem 2003; 90:424-436
13. Chenu C: Glutamatergic innervation in bone. Microsc Res Tech 2002; 58:70-76
14. Seibel MJ, Woitge HW: Basic principles and clinical applications of biochemical markers of bone metabolism. J Clin Densitom 1999; 2:299-321
15. Watts NB: Clinical utility of biochemical markers of bone remodelling. Clin Chem 1999; 45:1359-1368
16. Ahmad AM, Hopkins MT, Fraser WD, et al: Parathyroid hormone secretary pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency. Bone 2003; 32:170-179
17. 2. J Cell Physiol 2000; 183:163-171
18. 3. Bone 2001; 29:231-235
19. Wu Y, Kumar R: Parathyroid hormone regulates transforming growth factor β1 and β2 synthesis in osteoblasts via divergent signaling pathways. J Bone Miner Res 2000; 15: 879-884
20. Teasdale GM, Jennett B: Assessment of coma and impaired consciousness: A practical scale. Lancet 1974; 2:81-84
21. Broyles DL, Nielsen RG, Busset EM, et al: Analytic and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum alkaline phosphatase. Clin Chem 1998; 10:2139-2147
22. England TE, Samsoondar J, Maw G: Evaluation of the Hybritech Tandem-R Ostase immunoradiometric assay for skeletal alkaline phosphatase. Clin Biochem 1994; 27:187-189
23. Wildburger R, Zarkovic N, Dobnig H, et al: Post-traumatic dynamic change of carboxy-terminal propeptide of type 1 procollagen, alkaline phosphatase and its isoenzymes as predictors for enhanced osteogenesis in patients with severe head injury. Res Exp Med 1994; 194:247-259
24. Takahashi M, Naitou K, Ohishi T, et al: Comparison of biochemical markers of bone turn-over and bone mineral density between hip fracture and vertebral fracture. J Clin Densitom 2003; 6:211-218
25. Tanigushi T, Matsumoto T, Shindo H: Changes of serum levels of osteocalcin, alkaline phosphatase, IGF-1 and IGF-binding protein-3 during fracture healing. Injury Int J Care 2003; 34:477-479
26. Risteli J, Elomaa I, Niemi S, et al: Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type1 collagen: A new serum marker of bone collagen degradation. Clin Chem 1993; 39:635-640
27. Banse X, Devogelaer JP, Lafosse A, et al: Cross-link profile of bone collagen correlates with structural organisation of trabeculae. Bone 2002; 31:70-76
28. Miyakawa M, Tsushima T, Demura H: Carboxy-terminal propeptide of type 1 procollagen (PICP) and carboxy-terminal telopeptide of type 1 collagen (ICTP) as sensitive markers of bone metabolism in thyroid disease. Endocr J 1996; 43:701-708
29. Ducy P: Cbfa1: A molecular switch in osteoblast biology. Dev Dyn 2000; 219:461-471
30. Roach HI: Why does bone matrix contain non-collagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption. Cell Biol Int 1994; 18:617-628
31. Lian JB, Stein GS, Stein JL, et al: Osteocalcin gene promotor: Unlocking the secrets for regulation of osteoblast growth and differentiation. J Cell Biochem Suppl 1998; 30/31:62-72
32. Chenu C, Colucci S, Grano M, et al: Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells. J Cell Biol 1994; 127:1149-1158
33. Desbois C, Hongue DA, Karsenty G: The mouse osteocalcin gene cluster contains three genes with two separate spatial and temporal patterns of expression. J Biol Chem 1994; 269:1183-1190
34. Ducy P, Desbois C, Boyce B, et al: Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382:448-452
35. Cornish J, Callon KE, Lin C, et al: Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. J Bone Miner Res 1999; 14:915-1512
36. Swarthout JT, Alonzo RCD, Selvamurugan N, et al: Parathyroid hormone-dependent signalling pathways regulating genes in bone cells. Gene 2002; 282:1-17
37. Yu XP, Chandrasekhar S: Parathyroid hormone (PTH 1-34) regulation of rat osteocalcin gene transcription. Endocrinology 1997; 138:3085-3092
38. Fuller K, Owens JM, Chambers TJ: Induction of osteoclast formation by parathyroid hormone depends on action on stromal cells. J Endocrinol 1998; 158:341-350
39. Sexton PM, Findlay DM, Martin TJ: Calcitonin. Curr Med Chem 1999; 6:1067-1093
40. Susuki H, Nakamura I, Takahashi N, et al: Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology 1996; 137:4685-4690
41. Zaidi M, Moonga BS, Abe E: Calcitonin and bone formation: A knockout full of surprises. J Clin Invest 2002; 110:1769-1771
42. Ducy P, Amling M, Takeda S, et al: Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000; 100:197-207
43. Takeda S, Elefteriou F, Levasseur R, et al: Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111:305-317
44. Hoff AO: Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 2002; 110:1849-1857